Press Releases

 
Press Releases
  Date Summary View
Jun 14, 2016
NOVATO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:Julie Anne Smith, President and Chief Executive Officer, will participate in a fireside chat and provide an overview of the company at the 2016 J...
Jun 10, 2016
NOVATO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIRTM to inhaled tobramycin so...
Jun 7, 2016
NOVATO, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studie...
May 5, 2016
PROCYSBI® Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense Guidance Lowered to $125 — $135 Million   ...
Apr 28, 2016
NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to ...
Apr 11, 2016
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomon...
Mar 21, 2016
NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. ...
Mar 16, 2016
Granted for Three Distinct Indications:  Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous Mycobacteria Pre-NDA Discussio...
Mar 1, 2016
NOVATO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith, President and Chief Executive Officer, will participate in the Cowen and Company 36th Annual Healt...
Feb 29, 2016
NOVATO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Week, beginning February 29, 2016, with a series of activities and events that will celebrate advancements in the field of rare and orphan diseases and support and strengthen patient communities. The company...
Page:
1
... NextLast
= add release to Briefcase